

StemRIM Announces Patent Registration (Australia) for the Use of the HMGB1 Fragment Peptide, Redasemtide, as an Additional Therapeutic Indication for Cardiomyopathy and Old Myocardial Infarction

Osaka, Japan, June 17, 2024 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; “StemRIM” or “Company”) announces that a medical use patent for the “Regeneration-Inducing Medicine™” development candidate, Redasemtide, indicated for cardiomyopathy, old myocardial infarction, and chronic heart failure associated with them, will soon be registered in Australia.

Title of Invention : Therapeutic agent for cardiomyopathy, old myocardial infarction, and chronic heart failure
Region : Commonwealth of Australia
Application No. : 2018213671
Registration No. : To be determined
Applicant : StemRIM Inc., Osaka University

This patent is intended to expand the indications for Redasemtide, which is currently under development, and we believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy, old myocardial infarction, and chronic heart failure in Australia.

To date, we have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents.

The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine

products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.

Management & Administrator Dept.

E-Mail: stemrim-ir@stemrim.com

Twitter: [@StemRIM_Inc](https://twitter.com/StemRIM_Inc)

For more information, please visit the StemRIM website (<https://stemrim.com/english/>)